

**INFORME DE BÚSQUEDA SISTEMÁTICA DE EVIDENCIA DE LOS  
EFECTOS DESEABLES E INDESEABLES**

**Guía de Práctica Clínica Trastorno Ansioso**

**2018**



## ÍNDICE

TABLA RESUMEN	2
ESTRATEGIA DE BÚSQUEDA	3
CRITERIOS DE INCLUSIÓN	3
RECOLECCIÓN, ANÁLISIS Y SÍNTESIS DE DATOS	4
Selección de las revisiones	4
Extracción de datos	4
Mapeo de la evidencia	4
Apéndice 1. Estrategias de búsqueda:	5
Apéndice 2. Diagrama de flujo PRISMA	7
Apéndice 3. Referencias seleccionadas	8

## TABLA RESUMEN

<b>Problema de salud</b>	Trastorno Ansioso
<b>ICD10</b>	F60.6
<b>Fecha de entrega</b>	01/12/2018
<b>Investigador responsable</b>	Gabriel Rada Giacaman
<b>Número de revisiones sistemáticas</b>	124
<b>Número de preguntas</b>	470
<b>L·OVE</b>	<i>Generalized anxiety disorder</i>
<b>L·OVE URL</b>	<a href="https://love.epistemonikos.org/loves/5b8e8641d5e4d2506ec6fec8">https://love.epistemonikos.org/loves/5b8e8641d5e4d2506ec6fec8</a>

## ESTRATEGIA DE BÚSQUEDA

Se realizaron búsquedas en Epistemonikos, una base de datos exhaustiva de revisiones sistemáticas relevantes para la toma de decisiones en salud. La búsqueda de evidencia fue realizada en las siguientes bases de datos<sup>1</sup> con las estrategias descritas en el Apéndice 1.

1. Cochrane database of systematic reviews (CDSR)
2. Database of Abstracts of Reviews of Effectiveness (DARE)
3. HTA Database
4. PubMed
5. LILACS
6. CINAHL.
7. PsychINFO.
8. EMBASE.
9. EPPI-Centre Evidence Library
10. 3ie Systematic Reviews and Policy Briefs Campbell Library
11. Clinical Evidence.
12. SUPPORT Summaries
13. WHO Institutional Repository for Information Sharing
14. NICE public health guidelines and systematic reviews
15. ACP Journal Club.
16. Evidencias en Pediatría
17. The JBI Database of Systematic Reviews and Implementation Reports

## CRITERIOS DE INCLUSIÓN

Consideramos todas las revisiones sistemáticas que están sintetizando estudios primarios (tanto experimentales como observacionales) de acuerdo a la definición empleada por la Colaboración Cochrane y la declaración PRISMA.<sup>2</sup>

Una revisión elegible debe cumplir con los siguientes criterios operacionales:

1. Reporta una búsqueda en al menos una base de datos electrónica.
2. Reporta al menos uno de los siguientes criterios inclusión de los estudios:
  - **Tipo de participantes:** Se incluyen todas las revisiones sistemáticas que resuman estudios que respondan la pregunta acerca de intervenciones para Trastorno Ansioso.
  - **Tipo de desenlaces:** Se incluyen revisiones que presentan una síntesis (cuantitativa o cualitativa) de al menos un desenlace importante para el paciente u otra información

---

<sup>1</sup> La actualización se realiza de manera semanal. Se encuentra disponible en la plataforma digital un sistema de alerta que permite informar a través de correo electrónico la publicación de nuevos estudios que dan respuesta a las preguntas definidas, de manera de mantener continuamente actualizada la evidencia.

<sup>2</sup> “Una revisión sistemática intenta recopilar toda la evidencia empírica para responder a una pregunta de investigación específica, que cumple con criterios previamente definidos. Utiliza métodos explícitos y sistemáticos, que se eligen con miras a minimizar el sesgo, de manera de entregar hallazgos confiables que permitan sacar conclusiones y tomar decisiones”.

relevante para tomar decisiones poblacionales o individuales acerca de intervenciones para Trastorno Ansioso.

## RECOLECCIÓN, ANÁLISIS Y SÍNTESIS DE DATOS

### SELECCIÓN DE LAS REVISIONES

Al menos dos revisores, de manera independiente, realizaron el cribado de los títulos y resúmenes para identificar los artículos relevantes. El texto completo de las revisiones potencialmente elegibles fue recuperado y evaluado, de manera independiente, para su inclusión final. Un tercer investigador resolvió cualquier discrepancia que pudiera haberse provocado entre los distintos revisores.

### MAPEO DE LA EVIDENCIA

Con el objetivo de generar un listado exhaustivo de todas las posibles preguntas relacionadas con el tópico del L-OVE: *Trastorno Ansioso*<sup>3</sup>, se realiza la agrupación de las revisiones resultantes en formato PICO, es decir: población, intervención, comparación y desenlace [*outcome*]) utilizamos las siguientes fuentes:

1. Guías y documentos
2. Criterios de inclusión de las revisiones sistemáticas identificadas
3. Consulta con expertos
4. Retroalimentación de los usuarios

Como resultado final la plataforma incluye toda la evidencia disponible en revisiones sistemáticas y sus estudios primarios incluidos, segregada por nodos de evidencia que representan cada una de las preguntas priorizadas para actualización de la guía (Ver “Diagrama de flujo PRISMA” en Apéndice 2 y “Referencia Seleccionada” en Apéndice 3).

### ACTUALIZACIÓN – “LIVING”

Todas las búsquedas a través de esta plataforma se mantienen continuamente actualizada gracias a la tecnología implementada en el buscador de Epistemonikos y sus distintos colaboradores. Por lo cual, tanto la cantidad de revisiones, preguntas, entre otros datos cambian continuamente. Los datos presentados en este informe son los correspondientes a la fecha de entrega.

---

<sup>3</sup>Ver resultados de la búsqueda en: <https://love.epistemonikos.org/loves/5b8e8641dbe4d2506ec6fec8>

## APÉNDICE 1. ESTRATEGIAS DE BÚSQUEDA:<sup>4</sup>

Cochrane Library - Cochrane database of systematic reviews (CDSR)

<http://www.thecochranelibrary.com>

(anxiety OR anxious) AND (generali\* OR neurotic OR neuros\*), in Title, Abstract, Keywords:  
Cochrane Reviews (Reviews NOT protocols)

Medline/PubMed - US National Library of Medicine

<http://www.ncbi.nlm.nih.gov/pubmed/>

(anxiety OR anxious) AND (generali\* OR neurotic OR neuros\*) AND (MEDLINE[Title/Abstract]  
OR (systematic[Title/Abstract] AND review[Title/Abstract]) OR meta analysis[Publication  
Type])

EMBASE (Excerpta Medica dataBASE)

<http://www.embase.com>

Frequency of search: weekly  
(anxiety OR anxious) AND (generali\* OR neurotic OR neuros\*) AND (meta-analysis.tw.  
OR systematic review.tw)

CINAHL (Cumulative Index to Nursing and Allied Health Literature)

<https://www.ebscohost.com/nursing/products/cinahl-databases/the-cinahl-database>

(anxiety OR anxious) AND (generali\* OR neurotic OR neuros\*) AND ((TI meta analys\* or AB  
meta analys\*) or (TI systematic review or AB systematic review))

PsycINFO

<http://www.apa.org/pubs/databases/psycinfo>

(anxiety OR anxious) AND (generali\* OR neurotic OR neuros\*) AND (meta-analysis OR  
search\*)

LILACS (Literatura Latinoamericana y del Caribe en Ciencias de la Salud)

<http://lilacs.bvsalud.org/en/>

(anxiety OR anxious) AND (generali\* OR neurotic OR neuros\*) AND (tw:"revision sistematica"  
or tw:"revisao sistematica" or tw:"systematic review") or ((MH:"Literatura de Revisión como  
asunto" OR MH:"Metanálisis como asunto" OR PT:Revision OR PT:Metanálisis) and  
(TW:Metaanal\$ OR TW:"Meta-analysis" OR TW:"Meta-analise" OR TW:"Meta-analisis" OR  
TI:overview\$ or TW:"estudio sistematico" OR TW:"systematic study" OR TW:"estudo  
sistematico" OR TI:review OR TI:revisao OR TI:revision))

---

<sup>4</sup> No se aplican restricciones en base al idioma o estado de publicación.

DARE (Database of Abstracts of Reviews of Effectiveness) - Centre for Reviews and Dissemination, University of York

<http://www.crd.york.ac.uk/CRDWeb/>

(anxiety OR anxious) AND (generali\* OR neurotic OR neuros\*), in Any field: CRD assessed review (bibliographic)/ CRD assessed review (full abstract)

HTA

Database

<http://www.crd.york.ac.uk/CRDWeb/>

(anxiety OR anxious) AND (generali\* OR neurotic OR neuros\*), in Any field

The Campbell Collaboration Online Library

<https://www.campbellcollaboration.org/library.html>

(anxiety OR anxious) AND (generali\* OR neurotic OR neuros\*), in Title: Review

JBI Database of Systematic Reviews and Implementation Reports

<http://journals.lww.com/jbisrir/pages>


(anxiety OR anxious) AND (generali\* OR neurotic OR neuros\*) AND (review OR meta\*), in All fields

EPPI-Centre Evidence Library

<http://eppi.ioe.ac.uk/cms/Default.aspx?tabid=56>

(anxiety OR anxious) AND (generali\* OR neurotic OR neuros\*) All records in chronological list  
(<http://eppi.ioe.ac.uk/cms/Default.aspx?tabid=62>)

## APÉNDICE 2. DIAGRAMA DE FLUJO PRISMA





### APÉNDICE 3. REFERENCIAS SELECCIONADAS

1. Stein DJ, Baldwin DS, Baldinetti F, Mandel F. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology*. 2008;18(6):422-30. [www.epistemonikos.org/documents/01181d88e7f87fd8aae60949e34ede9762d7d635](http://www.epistemonikos.org/documents/01181d88e7f87fd8aae60949e34ede9762d7d635)
2. Baldwin, David, Woods, Robert, Lawson, Richard, Taylor, David, University of Southampton Faculty of Medicine, University Department of Psychiatry, Academic Centre, Southampton S014 3DT, UK. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. *BMJ: British Medical Journal (Overseas & Retired Doctors Edition)*. 2011;342(7798):637-637. [www.epistemonikos.org/documents/061f484dcb31f676095aab0ffe563373dcf4b6ed](http://www.epistemonikos.org/documents/061f484dcb31f676095aab0ffe563373dcf4b6ed)
3. Tully PJ, Cosh SM. Generalized anxiety disorder prevalence and comorbidity with depression in coronary heart disease: a meta-analysis. *Journal of health psychology*. 2013;18(12):1601-16. [www.epistemonikos.org/documents/15b05ebdb5cd53dc35aa61d57952a4cecf3b05f4](http://www.epistemonikos.org/documents/15b05ebdb5cd53dc35aa61d57952a4cecf3b05f4)
4. Zhang Y, Huang G, Yang S, Liang W, Zhang L, Wang C. Duloxetine in treating generalized anxiety disorder in adults: A meta-analysis of published randomized, double-blind, placebo-controlled trials. *Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists*. 2016;8(3):215-25. [www.epistemonikos.org/documents/1c5983303518be8714f205fe3137d6131b45dc5a](http://www.epistemonikos.org/documents/1c5983303518be8714f205fe3137d6131b45dc5a)
5. Hall J, Kellett S, Berrios R, Bains MK, Scott S. Efficacy of Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults: Systematic Review, Meta-Analysis, and Meta-Regression. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*. 2016;24(11):1063-1073. [www.epistemonikos.org/documents/1d4b5e2d1a1bdc599be0128cfbe5b04093ed6fbc](http://www.epistemonikos.org/documents/1d4b5e2d1a1bdc599be0128cfbe5b04093ed6fbc)
6. Bech P. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. *Pharmacopsychiatry*. 2007;40(4):163-8. [www.epistemonikos.org/documents/1df55862c3e0be0e4702a6494d023b40485df25a](http://www.epistemonikos.org/documents/1df55862c3e0be0e4702a6494d023b40485df25a)
7. Donovan MR, Glue P, Kolluri S, Emir B. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysis. *Journal of affective disorders*. 2010;123(1-3):9-16. [www.epistemonikos.org/documents/215a0a4ad0e8c7bfb8c1740b9c4498e222362dc4](http://www.epistemonikos.org/documents/215a0a4ad0e8c7bfb8c1740b9c4498e222362dc4)
8. Martin JL, Sainz-Pardo M, Furukawa TA, Martín-Sánchez E, Seoane T, Galán C. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. *Journal of psychopharmacology (Oxford, England)*. 2007;21(7):774-82. [www.epistemonikos.org/documents/2451ff034b3309877eec601985b84db19274cf27](http://www.epistemonikos.org/documents/2451ff034b3309877eec601985b84db19274cf27)
9. Ferreira-Garcia R., Mochcovitch M., Costa do Cabo M., Nardi A.E., Christophe Freire R.. Predictors of Pharmacotherapy Response in Generalized Anxiety Disorder: A Systematic Review. *Harvard Review of Psychiatry*. 2017;25(2):65-79. [www.epistemonikos.org/documents/2b2eeb3aa2f254d3bc048e4b80d018e7124e37fa](http://www.epistemonikos.org/documents/2b2eeb3aa2f254d3bc048e4b80d018e7124e37fa)
10. Alves, Verônica de Medeiros, Moura, Edilson Leite de, Correia, Larissa Tenório Andrade, Nardi, Antonio E. Genetic Polymorphisms and Generalized Anxiety Disorder: a systematic review. *MedicalExpress (São Paulo, Online)*. 2017;4(1). [www.epistemonikos.org/documents/2b6bc928ff3ea21ecf87d0eed10cc3710b73e887](http://www.epistemonikos.org/documents/2b6bc928ff3ea21ecf87d0eed10cc3710b73e887)
11. Mochcovitch MD, da Rocha Freire RC, Garcia RF, Nardi AE. Can Long-Term Pharmacotherapy Prevent Relapses in Generalized Anxiety Disorder? A Systematic Review. *Clinical drug investigation*. 2017;37(8):1-7. [www.epistemonikos.org/documents/3436ff4b73ee1744d396bcddf796791290793eff](http://www.epistemonikos.org/documents/3436ff4b73ee1744d396bcddf796791290793eff)
12. Generoso MB, Trevizol AP, Kasper S, Cho HJ, Cordeiro Q, Shiozawa P. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. *International clinical psychopharmacology*. 2017;32(1):49-55. [www.epistemonikos.org/documents/371719710f5a40bcb52c507e27b01d97f30e5b3d](http://www.epistemonikos.org/documents/371719710f5a40bcb52c507e27b01d97f30e5b3d)

13. Benjamin S, Herr NR, McDuffie J, Nagi A, Williams JW. Performance Characteristics of Self-Report Instruments for Diagnosing Generalized Anxiety and Panic Disorders in Primary Care: A Systematic Review. VA Evidence-based Synthesis Program Reports. 2011;[www.epistemonikos.org/documents/37b786d87357627e37412e39499493ce9ccf548c](http://www.epistemonikos.org/documents/37b786d87357627e37412e39499493ce9ccf548c)
14. Hanrahan F, Field AP, Jones FW, Davey GC. A meta-analysis of cognitive therapy for worry in generalized anxiety disorder. *Clinical psychology review*. 2013;33(1):120-32.[www.epistemonikos.org/documents/3912782c3ea0c24bf5aabae3abee58e4571fbb7a](http://www.epistemonikos.org/documents/3912782c3ea0c24bf5aabae3abee58e4571fbb7a)
15. Parmentier H, García-Campayo J, Prieto R. Comprehensive review of generalized anxiety disorder in primary care in Europe. *Current medical research and opinion*. 2013;29(4):355-67.  
[www.epistemonikos.org/documents/3e1593165ad98d3fa13888930c345fe55388c284](http://www.epistemonikos.org/documents/3e1593165ad98d3fa13888930c345fe55388c284)
16. Goodwin H, Yiend J, Hirsch CR. Generalized Anxiety Disorder, worry and attention to threat: A systematic review. *Clinical psychology review*. 2017;54:107-122.[www.epistemonikos.org/documents/440a9553f7c16ae5acc352f9b835282662216d2f](http://www.epistemonikos.org/documents/440a9553f7c16ae5acc352f9b835282662216d2f)
17. Barić H, Đorđević V, Cerovečki I, Trkulja V. Complementary and Alternative Medicine Treatments for Generalized Anxiety Disorder: Systematic Review and Meta-analysis of Randomized Controlled Trials. *Advances in therapy*. 2018;35(3):261-288.  
[www.epistemonikos.org/documents/4727ef869d794ccd3196bd3857c3ff18cd9da15f](http://www.epistemonikos.org/documents/4727ef869d794ccd3196bd3857c3ff18cd9da15f)
18. Haller H, Cramer H, Lauche R, Gass F, Dobos GJ. The prevalence and burden of subthreshold generalized anxiety disorder: a systematic review. *BMC psychiatry*. 2014;14(1):128.  
[www.epistemonikos.org/documents/4abe0d9e615a5bcc04ab785646ef39317e589577](http://www.epistemonikos.org/documents/4abe0d9e615a5bcc04ab785646ef39317e589577)
19. Haby MM, Donnelly M, Corry J, Vos T. Cognitive behavioural therapy for depression, panic disorder and generalized anxiety disorder: a meta-regression of factors that may predict outcome. *The Australian and New Zealand journal of psychiatry*. 2006;40(1):9-19.[www.epistemonikos.org/documents/4ebe408a7acb251eef8ce1abe63843c150777109](http://www.epistemonikos.org/documents/4ebe408a7acb251eef8ce1abe63843c150777109)
20. Zhang Y.-Q., Fan K.-H., Jin W.-H., Li D., Mi T.-T.. Effectiveness and safety of trazodone versus alprazolam for adults' generalized anxiety disorder: A meta-analysis. *Chinese Journal of Evidence-Based Medicine*. 2013;13(1):100-105.  
[www.epistemonikos.org/documents/4f03ccb402a236e9afc0611d5388d652c151ab0c](http://www.epistemonikos.org/documents/4f03ccb402a236e9afc0611d5388d652c151ab0c)
21. Swedish Council on Health Technology Assessment. Treatment of Anxiety Disorders: A Systematic Review. SBU Systematic Review Summaries. 2005;[www.epistemonikos.org/documents/52b4f1b724fb426b6a165e806c3337dd76782815](http://www.epistemonikos.org/documents/52b4f1b724fb426b6a165e806c3337dd76782815)
22. Allgulander C, Hartford J, Russell J, Ball S, Erickson J, Raskin J, Rynn M. Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials. *Current medical research and opinion*. 2007;23(6):1245-52.[www.epistemonikos.org/documents/52fbb66256b321b5d9a5d63b25193c285257d8d7](http://www.epistemonikos.org/documents/52fbb66256b321b5d9a5d63b25193c285257d8d7)
23. Zou C, Ding X, Flaherty JH, Dong B. Clinical efficacy and safety of fluoxetine in generalized anxiety disorder in Chinese patients. *Neuropsychiatric disease and treatment*. 2013;9:1661-1670.  
[www.epistemonikos.org/documents/57d7d2ef0605518212e01f4ed4f703faf9cdc285](http://www.epistemonikos.org/documents/57d7d2ef0605518212e01f4ed4f703faf9cdc285)
24. Boschen MJ. A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder. *Canadian journal of psychiatry. Revue canadienne de psychiatrie*. 2011;56(9):558-66.  
[www.epistemonikos.org/documents/581e061c01d3c9a73be1c95e089d3e94e9b851b1](http://www.epistemonikos.org/documents/581e061c01d3c9a73be1c95e089d3e94e9b851b1)
25. Montoya, Alonso, Bruins, Robert, Katzman, Martin A., Blier, Pierre. The noradrenergic paradox: Implications in the management of depression and anxiety. *Neuropsychiatric Disease and Treatment*. 2016;12:541-57.  
[www.epistemonikos.org/documents/58e7ce45a0096165f66684cd8f1992fe3917a95d](http://www.epistemonikos.org/documents/58e7ce45a0096165f66684cd8f1992fe3917a95d)
26. Kreys TJ, Phan SV. A literature review of quetiapine for generalized anxiety disorder. *Pharmacotherapy*. 2015;35(2):175-88.[www.epistemonikos.org/documents/5d4bb427f9c448c0aca5bf76db359a23b50b320f](http://www.epistemonikos.org/documents/5d4bb427f9c448c0aca5bf76db359a23b50b320f)
27. Schmitt, Ricardo, Gazalle, Fernando Kratz, Lima, Maurício Silva de, Cunha, Angelo, Souza, Juliano, Kapczinski, Flávio. The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis. *Rev. bras. psiquiatr*. 2005;27(1):18-24.[www.epistemonikos.org/documents/5dbd0c079a7ae0fa3ab9d6fcb43bc51667508f79](http://www.epistemonikos.org/documents/5dbd0c079a7ae0fa3ab9d6fcb43bc51667508f79)

28. Faustino TT, Almeida RB, Andreatini R. [Medicinal plants for the treatment of generalized anxiety disorder: a review of controlled clinical studies]. *Revista brasileira de psiquiatria (São Paulo, Brazil : 1999)*. 2010;32(4):429-36.  
www.epistemonikos.org/documents/6035fad38b477dd85db902a3cfb07b8ba895380b
29. Huh J, Goebert D, Takeshita J, Lu BY, Kang M. Treatment of generalized anxiety disorder: a comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines. *The primary care companion for CNS disorders*. 2011;13(2).www.epistemonikos.org/documents/632a15f0f8fbd30601b6bc19d4a852f40b99ae1e
30. Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. *BMJ (Clinical research ed.)*. 2011;342:d1199.  
www.epistemonikos.org/documents/65913cff225582c92cc68fd264bb530ff823ea03
31. Lakhan SE, Vieira KF. Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. *Nutrition journal*. 2010;9(1):42.  
www.epistemonikos.org/documents/72b5156674a7f84e05b4668ad79f6fa6939cd38c
32. Gonçalves DC, Byrne GJ. Interventions for generalized anxiety disorder in older adults: systematic review and meta-analysis. *Journal of anxiety disorders*. 2012;26(1):1-11.  
www.epistemonikos.org/documents/73ade53714753fb9c89e886f6b74cf4178aff1d4
33. Revicki DA, Travers K, Wyrwich KW, Svedsäter H, Locklear J, Mattera MS, Sheehan DV, Montgomery S. Humanistic and economic burden of generalized anxiety disorder in North America and Europe. *Journal of affective disorders*. 2012;140(2):103-12.  
www.epistemonikos.org/documents/756e12c453b3ca9205740420563469654de618d9
34. Gao K, Kemp DE, Fein E, Wang Z, Fang Y, Ganocy SJ, Calabrese JR. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. *The Journal of clinical psychiatry*. 2011;72(8):1063-71.  
www.epistemonikos.org/documents/75e2efadeaec4528068eeb7b7b41ef36eae3b6d
35. von Knorring L, Thelander S, Pettersson A. [Treatment of anxiety syndrome. A systematic literature review. Summary and conclusions by the SBU]. *Läkartidningen*. 2005;102(47):3561-2, 3565-6, 3569.  
www.epistemonikos.org/documents/7b71d3987a20b22d30e8b702758d317f93499b42
36. Gajic-Veljanoski, Olga, Sanyal, Chiranjeev, McMartin, Kristen, Xuanqian Xie, Walter, Melissa, Higgins, Caroline, Sikich, Nancy, Dhalla, Irfan A., Ng, Vivian. Economic Evaluations of Commonly Used Structured Psychotherapies for Major Depressive Disorder and Generalized Anxiety Disorder: A Systematic Review. *Canadian Psychology*. 2018;59(4):301-314.  
www.epistemonikos.org/documents/846f361856a5a220e71c5c59ed5ecab2f0a053c8
37. Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. *International clinical psychopharmacology*. 2015;30(4):183-92.  
www.epistemonikos.org/documents/88803e97b42a25b105f4e97a1162a207dc693e71
38. Cuijpers P, Sijbrandij M, Koole S, Huibers M, Berking M, Andersson G. Psychological treatment of generalized anxiety disorder: a meta-analysis. *Clinical psychology review*. 2014;34(2):130-140.  
www.epistemonikos.org/documents/8b0a9d43d8a695500a245ca30340e5e155a38310
39. Li X, Zhu L, Zhou C, Liu J, Du H, Wang C, Fang S. Efficacy and tolerability of short-term duloxetine treatment in adults with generalized anxiety disorder: A meta-analysis. *PLoS one*. 2018;13(3):e0194501.  
www.epistemonikos.org/documents/8c39efb877290d575d36fa12e27d53e557642600
40. Gammans RE, Stringfellow JC, Hvizdos AJ, Seidehamel RJ, Cohn JB, Wilcox CS, Fabre LF, Pecknold JC, Smith WT, Rickels K. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies. *Neuropsychobiology*. 1992;25(4):193-201.  
www.epistemonikos.org/documents/8cd5927dcdcf7c4aa68c51cc73797e2c8b8ea53c

41. Wang Z, Whiteside S, Sim L, Farah W, Morrow A, Alsawas M, Moreno PB, Tello M, Asi N, Beuschel B, Daraz L, Almasri J, Zaiem F, Gunjal S, Mantilla LL, Ponte OP, LeBlanc A, Prokop LJ, Murad MH. Anxiety in Children. *AHRQ Comparative Effectiveness Reviews*. 2017;[www.epistemonikos.org/documents/8f808f947e12505b06cd7ee2811dc2d3a3bafd4e](http://www.epistemonikos.org/documents/8f808f947e12505b06cd7ee2811dc2d3a3bafd4e)
42. Gomez AF, Barthel AL, Hofmann SG. Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. *Expert opinion on pharmacotherapy*. 2018;19(8):1-12. [www.epistemonikos.org/documents/931571929db1a51a7574d987e94ff8d2e307309d](http://www.epistemonikos.org/documents/931571929db1a51a7574d987e94ff8d2e307309d)
43. Wang S., Zhao L.-L., Qiu X.-J., Wang D.-S., Tang T., Luo J.-K., Hu S.-Y., Huang H.-Y.. Efficacy and Safety of a Formulated Herbal Granula, Jiu Wei Zhen Xin, for Generalized Anxiety Disorder: A Meta-Analysis. *Evidence-based Complementary and Alternative Medicine*. 2018;2018(no pagination).[www.epistemonikos.org/documents/963b37860ecc3e8ae55a50b6952a681ec6b12698](http://www.epistemonikos.org/documents/963b37860ecc3e8ae55a50b6952a681ec6b12698)
44. Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. *Cochrane Database of Systematic Reviews*. 2010;(12):CD006815.[www.epistemonikos.org/documents/a1cd9ca830a488aa9b9fee6c4b30eaac72111c82](http://www.epistemonikos.org/documents/a1cd9ca830a488aa9b9fee6c4b30eaac72111c82)
45. Ipser JC, Wilson D, Akindipe TO, Sager C, Stein DJ. Pharmacotherapy for anxiety and comorbid alcohol use disorders. *Cochrane Database of Systematic Reviews*. 2015;1(1):CD007505. [www.epistemonikos.org/documents/a680f6e7130a5b983315f19767c878c532db88b8](http://www.epistemonikos.org/documents/a680f6e7130a5b983315f19767c878c532db88b8)
46. Mochcovitch MD, da Rocha Freire RC, Garcia RF, Nardi AE. A systematic review of fMRI studies in generalized anxiety disorder: evaluating its neural and cognitive basis. *Journal of affective disorders*. 2014;167((Mochcovitch M.D., marimochco@yahoo.com.br; Da Rocha Freire R.C.; Garcia R.F.; Nardi A.E.) Federal University of Rio de Janeiro, Rio de Janeiro, Brazil):336-42. [www.epistemonikos.org/documents/a93a5d1140ccce5dcd5441543248c9d51674b2b8](http://www.epistemonikos.org/documents/a93a5d1140ccce5dcd5441543248c9d51674b2b8)
47. Bereza BG, Machado M, Ravindran AV, Einarson TR. Evidence-based review of clinical outcomes of guideline-recommended pharmacotherapies for generalized anxiety disorder. *Canadian journal of psychiatry. Revue canadienne de psychiatrie*. 2012;57(8):470-8.[www.epistemonikos.org/documents/a98ba419b457052e0db197d43652c8128ca6cb1f](http://www.epistemonikos.org/documents/a98ba419b457052e0db197d43652c8128ca6cb1f)
48. Gentes EL, Ruscio AM. A meta-analysis of the relation of intolerance of uncertainty to symptoms of generalized anxiety disorder, major depressive disorder, and obsessive-compulsive disorder. *Clinical psychology review*. 2011;31(6):923-33. [www.epistemonikos.org/documents/a9f5cc776395ddb089bef3db8b8dbe897f0c2995](http://www.epistemonikos.org/documents/a9f5cc776395ddb089bef3db8b8dbe897f0c2995)
49. Glue P., Loan A., Gale C.. New prospects for the drug treatment of generalized anxiety disorder - A systematic review. *Current Drug Therapy*. 2010;5(2):86-94.[www.epistemonikos.org/documents/abfaa5c7c549d4daa3a1a4efccd6b3960a459c23](http://www.epistemonikos.org/documents/abfaa5c7c549d4daa3a1a4efccd6b3960a459c23)
50. Mitte K. Meta-analysis of cognitive-behavioral treatments for generalized anxiety disorder: a comparison with pharmacotherapy. *Psychological bulletin*. 2005;131(5):785-95.[www.epistemonikos.org/documents/adca91d06b5211d8a51cfd85c000bb2509d7d772](http://www.epistemonikos.org/documents/adca91d06b5211d8a51cfd85c000bb2509d7d772)
51. Fu J, Peng L, Li X. The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: A meta-analysis. *Neuropsychiatric Disease and Treatment*. 2016;12:951-959. [www.epistemonikos.org/documents/b01e049f34761b68bb0ddd921f3b3e1b3e112d14](http://www.epistemonikos.org/documents/b01e049f34761b68bb0ddd921f3b3e1b3e112d14)
52. Samuel M, Zimovetz EA, Gabriel Z, Beard SM. Efficacy and safety of treatments for refractory generalized anxiety disorder: a systematic review. *International clinical psychopharmacology*. 2011;26(2):63-8. [www.epistemonikos.org/documents/b4dae5e3aae15cacaded103c93d6cf6160911fee](http://www.epistemonikos.org/documents/b4dae5e3aae15cacaded103c93d6cf6160911fee)
53. Vivien Hunot, Rachel Churchill, Vanessa Teixeira, Mauricio Silva de Lima. Psychological therapies for generalised anxiety disorder. *Cochrane Database of Systematic Reviews*. 2007;(1):CD001848. [www.epistemonikos.org/documents/b516e6044d4568212b37087aeb71656d704e65b7](http://www.epistemonikos.org/documents/b516e6044d4568212b37087aeb71656d704e65b7)
54. Perna G, Alciati A, Riva A, Micieli W, Caldirola D. Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review. *Current psychiatry reports*. 2016;18(3):23. [www.epistemonikos.org/documents/b58fb56e71fe5e074cd65d87b11d901b0b6f97b0](http://www.epistemonikos.org/documents/b58fb56e71fe5e074cd65d87b11d901b0b6f97b0)

55. Dobson ET, Strawn JR. Pharmacotherapy for Pediatric Generalized Anxiety Disorder: A Systematic Evaluation of Efficacy, Safety and Tolerability. *Paediatric drugs*. 2016;18(1):45-53.  
[www.epistemonikos.org/documents/b68a69b3e1ef0901a83247b0ab85bac4d1ba2e8e](http://www.epistemonikos.org/documents/b68a69b3e1ef0901a83247b0ab85bac4d1ba2e8e)
56. Maneeton N, Maneeton B, Woottitluk P, Likhitsathian S, Suttajit S, Boonyanaruthee V, Srisurapanont M. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. *Drug design, development and therapy*. 2016;10:259-76.  
[www.epistemonikos.org/documents/bb1a3a23aff69f2f1ee2554a4130fe8c45e5c441](http://www.epistemonikos.org/documents/bb1a3a23aff69f2f1ee2554a4130fe8c45e5c441)
57. Gersh E, Hallford DJ, Rice SM, Kazantzis N, Gersh H, Gersh B, McCarty CA. Systematic review and meta-analysis of dropout rates in individual psychotherapy for generalized anxiety disorder. *Journal of anxiety disorders*. 2017;52:25-33.  
[www.epistemonikos.org/documents/be6ad845e61641bc0d4135d04f249f3428ce9abb](http://www.epistemonikos.org/documents/be6ad845e61641bc0d4135d04f249f3428ce9abb)
58. Gao K, Muzina D, Gajwani P, Calabrese JR. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. *The Journal of clinical psychiatry*. 2006;67(9):1327-40.  
[www.epistemonikos.org/documents/c61079ab0cc4f5b6b2c17afe830efbf47d25643f](http://www.epistemonikos.org/documents/c61079ab0cc4f5b6b2c17afe830efbf47d25643f)
59. Ooi SL, Henderson P, Pak SC. Kava for Generalized Anxiety Disorder: A Review of Current Evidence. *Journal of alternative and complementary medicine (New York, N.Y.)*. 2018;24(8):770-780.  
[www.epistemonikos.org/documents/cd10a1d23bb44476ae64229a47c0e0c12e37656b](http://www.epistemonikos.org/documents/cd10a1d23bb44476ae64229a47c0e0c12e37656b)
60. Baldwin, David, Woods, Robert, Lawson, Richard, Taylor, David. Efficacy of drug treatments for generalised anxiety disorder: Systematic review and meta-analysis. *BMJ: British Medical Journal*. 2011;342(7798).  
[www.epistemonikos.org/documents/cee3a1b7bccd0f8ed32640beda794b4bb518d58f](http://www.epistemonikos.org/documents/cee3a1b7bccd0f8ed32640beda794b4bb518d58f)
61. Bereza BG, Machado M, Einarson TR. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder. *Clinical therapeutics*. 2009;31(6):1279-308.  
[www.epistemonikos.org/documents/cffe00c35b885f29ddaf2bdd8e5c561d64d55848](http://www.epistemonikos.org/documents/cffe00c35b885f29ddaf2bdd8e5c561d64d55848)
62. Schmitt R, Gazalle FK, Lima MS, Cunha A, Souza J, Kapczinski F. The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis. *Revista brasileira de psiquiatria (São Paulo, Brazil : 1999)*. 2005;27(1):18-24.  
[www.epistemonikos.org/documents/d63626e0add0d1e44ed00758eebddddee4e2ec66](http://www.epistemonikos.org/documents/d63626e0add0d1e44ed00758eebddddee4e2ec66)
63. Moreno-Peral P, Conejo-Cerón S, Motrico E, Rodríguez-Morejón A, Fernández A, García-Campayo J, Roca M, Serrano-Blanco A, Rubio-Valera M, Angel Bellón J. Risk factors for the onset of panic and generalised anxiety disorders in the general adult population: A systematic review of cohort studies. *Journal of affective disorders*. 2014;168C((Moreno-Peral P.; Conejo-Ceron S.; Angel Bellon J., jbellon@uma.es) Departamento de Medicina Preventiva, Universidad de Malaga, Campus de Teatinos, 29071 Malaga, Spain):337-348.  
[www.epistemonikos.org/documents/d7236e8878803167fe373e90a742990f354244fd](http://www.epistemonikos.org/documents/d7236e8878803167fe373e90a742990f354244fd)
64. Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Serretti A. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis. *Journal of psychiatric research*. 2015;64:88-98.  
[www.epistemonikos.org/documents/d7302ac84cf9c233b866b8d27ba44a83c1b9dd5d](http://www.epistemonikos.org/documents/d7302ac84cf9c233b866b8d27ba44a83c1b9dd5d)
65. Hidalgo RB, Tupler LA, Davidson JR. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. *Journal of psychopharmacology (Oxford, England)*. 2007;21(8):864-72. [www.epistemonikos.org/documents/d73e12b8ad36ab2729294571a3a9b18d241e62f6](http://www.epistemonikos.org/documents/d73e12b8ad36ab2729294571a3a9b18d241e62f6)
66. Mahe V, Balogh A. Long-term pharmacological treatment of generalized anxiety disorder. *International clinical psychopharmacology*. 2000;15(2):99-105.  
[www.epistemonikos.org/documents/dd118f1fc7731d47e6301284df76ffdaadc18bd8](http://www.epistemonikos.org/documents/dd118f1fc7731d47e6301284df76ffdaadc18bd8)
67. Richards D., Richardson T., Timulak L., McElvaney J.. The efficacy of internet-delivered treatment for generalized anxiety disorder: A systematic review and meta-analysis. *Internet Interventions*. 2015;2(3):272-282.  
[www.epistemonikos.org/documents/e07222c81e444e160a94d347352cb8f50c89bb25](http://www.epistemonikos.org/documents/e07222c81e444e160a94d347352cb8f50c89bb25)

68. Gale CK. The treatment of generalised anxiety disorder. A systematic review. *Panminerva medica*. 2002;44(4):283-  
6.[www.epistemonikos.org/documents/e3485cb03e5636decdb00b16ff42f557d694e8ff](http://www.epistemonikos.org/documents/e3485cb03e5636decdb00b16ff42f557d694e8ff)
69. Darbà J, Kaskens L, Pérez C, Alvarez E, Navarro-Artieda R, Sicras-Mainar A. Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective. *Advances in therapy*. 2014;31(1):1-  
29.[www.epistemonikos.org/documents/e5832e64c96acb09fd74daaab911344b2f894363](http://www.epistemonikos.org/documents/e5832e64c96acb09fd74daaab911344b2f894363)
70. Li X, Zhu L, Su Y, Fang S. Short-term efficacy and tolerability of venlafaxine extended release in adults with generalized anxiety disorder without depression: A meta-analysis. *PLoS one*. 2017;12(10):e0185865.  
[www.epistemonikos.org/documents/e6548f72ca886b1225093ae525dff9d477ad8d54](http://www.epistemonikos.org/documents/e6548f72ca886b1225093ae525dff9d477ad8d54)
71. Reinhold JA, Rickels K. Pharmacological treatment for generalized anxiety disorder in adults: an update. *Expert opinion on pharmacotherapy*. 2015;16(11):1669-  
1681.[www.epistemonikos.org/documents/e76e8c391fcc59d580bb18c015cb78d534502f61](http://www.epistemonikos.org/documents/e76e8c391fcc59d580bb18c015cb78d534502f61)
72. Zhu, Zhipei, Zhang, Li, Jiang, Jiangling, Li, Wei, Cao, Xinyi, Zhou, Zhirui, Zhang, Tiansong, Li, Chunbo. Comparison of psychological placebo and waiting list control conditions in the assessment of cognitive behavioral therapy for the treatment of generalized anxiety disorder: A meta-analysis. *Shanghai Archives of Psychiatry*. 2014;26(6):319-31.  
[www.epistemonikos.org/documents/e7e04b63ea32f0726a0b89a54d5c184298b98088](http://www.epistemonikos.org/documents/e7e04b63ea32f0726a0b89a54d5c184298b98088)
73. Zareifopoulos N., Dylja I.. Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: A meta-analysis. *Asian Journal of Psychiatry*. 2017;26:115-122.  
[www.epistemonikos.org/documents/e8191d68333241fe09e15303807174d7aa35ee4c](http://www.epistemonikos.org/documents/e8191d68333241fe09e15303807174d7aa35ee4c)
74. Hilbert K, Lueken U, Beesdo-Baum K. Neural structures, functioning and connectivity in Generalized Anxiety Disorder and interaction with neuroendocrine systems: a systematic review. *Journal of affective disorders*. 2014;158C:114-126.  
[www.epistemonikos.org/documents/e8a512eba6301e6d5da8896d989cbf0fb016d656](http://www.epistemonikos.org/documents/e8a512eba6301e6d5da8896d989cbf0fb016d656)
75. Kwon C.-Y., Choi E.-J., Suh H.-W., Chung S.-Y., Kim J.W.. Oriental herbal medicine for generalized anxiety disorder: A systematic review of randomized controlled trials. *European Journal of Integrative Medicine*. 2018;20:36-62.  
[www.epistemonikos.org/documents/e96c7b955c3498bae97a3c3770c6a9f6dacf750d](http://www.epistemonikos.org/documents/e96c7b955c3498bae97a3c3770c6a9f6dacf750d)
76. Cheryl A Chessick, Michael H Allen, Michael E. Thase, Angelo ABC Batista Miralha da Cunha, Flavio FK Kapczinski, Mauricio Silva de Lima, Juliano JSS dos Santos Souza. Azapirones for generalized anxiety disorder. *Cochrane Database of Systematic Reviews*. 2006;(3):CD006115.[www.epistemonikos.org/documents/ec67f252d5ec9a4a5f041e3f9ca0618f9b346dd5](http://www.epistemonikos.org/documents/ec67f252d5ec9a4a5f041e3f9ca0618f9b346dd5)
77. Westen D, Morrison K. A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorder: an empirical examination of the status of empirically supported therapies. *Journal of consulting and clinical psychology*. 2001;69(6):875-  
99.[www.epistemonikos.org/documents/eddb5c93ba95a1b7a4aa5a29687b3ae95a8df3df](http://www.epistemonikos.org/documents/eddb5c93ba95a1b7a4aa5a29687b3ae95a8df3df)
78. Ali E. Women's experiences with postpartum anxiety disorders: a narrative literature review. *International journal of women's health*. 2018;10:237-  
249.[www.epistemonikos.org/documents/f8e50d231976873032721e0a6801a01d8de3fb3f](http://www.epistemonikos.org/documents/f8e50d231976873032721e0a6801a01d8de3fb3f)
79. Orsolini L, Tomasetti C, Valchera A, Iasevoli F, Buonaguro EF, Vellante F, Fornaro M, Fiengo A, Mazza M, Vecchiotti R, Perna G, de Bartolomeis A, Martinotti G, Di Giannantonio M, De Berardis D. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. *Expert review of neurotherapeutics*. 2016;16(5):483-95.  
[www.epistemonikos.org/documents/f968f472c29d8528ee1d2b52351628650b5d3ecf](http://www.epistemonikos.org/documents/f968f472c29d8528ee1d2b52351628650b5d3ecf)
80. Mitte K, Noack P, Steil R, Hautzinger M. A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. *Journal of clinical psychopharmacology*. 2005;25(2):141-50.  
[www.epistemonikos.org/documents/fe5501401bab48c28fc2c9f43518306c968ab3d5](http://www.epistemonikos.org/documents/fe5501401bab48c28fc2c9f43518306c968ab3d5)

